IMMUNOCLOAK™

Systemic administration of immunosuppressive drugs to prevent the rejection of a transplanted kidney is the standard-of-care in clinical transplantation. However, the use of chronic immunosuppression therapy results in significant drug-induced side-effects and higher rates of both malignancies and opportunistic infections.

BREONICS has addressed this problem by developing an innovative technology that is a organ-specific treatment that can be applied pre-transplantation to a kidney allograft. BREONICS novel technology is referred to as “ImmunoCloak™” that is comprised of a bioengineered membrane containing type IV collagen, vitrogen, fibronectin and laminin. The ImmunoCloak™ polymerizes into a tri-dimensional membrane that binds to the surface of blood vessels within the vasculature of an allograft. The result is a bioengineered apical surface that is non-thrombogenic and non-immunogenic. Most importantly, the application of ImmunoCloak™ prevents the allo-recognition that normally occurs immediately following reperfusion when a kidney allograft is transplanted. BREONICS believes the prevention of normal allo-recognition that occurs immediately upon the restoration of blood flow results in prolonged allograft survival in the absence of system immunosuppression.